Greenwood Capital Associates LLC Purchases Shares of 14,451 Novo Nordisk A/S $NVO

Greenwood Capital Associates LLC bought a new position in Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 14,451 shares of the company’s stock, valued at approximately $531,000.

Several other hedge funds have also added to or reduced their stakes in NVO. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $25,000. WealthCollab LLC lifted its stake in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $28,000. Maseco LLP purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $48.93 on Friday. The business has a 50 day simple moving average of $45.39 and a two-hundred day simple moving average of $45.85. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $71.79. The stock has a market capitalization of $218.48 billion, a PE ratio of 11.49, a P/E/G ratio of 4.46 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. On average, research analysts predict that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the topic of a number of analyst reports. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wolfe Research started coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price for the company. Finally, Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched Awiqli, the world’s first once-weekly basal insulin, in India, expanding its diabetes portfolio in one of the world’s largest and fastest-growing diabetes markets. The rollout could provide a new growth avenue and reinforces the company’s leadership in diabetes care. Article Title
• Positive Sentiment: Another report highlighted the India insulin launch as a meaningful innovation for diabetes treatment, which may improve investor sentiment around Novo Nordisk’s long-term pipeline and international expansion. Article Title
• Positive Sentiment: A separate piece said Novo Nordisk remains undervalued despite the Wegovy label update, suggesting the market may still be pricing in a cautious outlook even as the company preserves a strong long-term obesity-drug story. Article Title
• Neutral Sentiment: Novo Nordisk also expanded its collaboration with MAHE’s GBS in pharmacometrics, a strategic but likely modest near-term market-moving development. Article Title
• Neutral Sentiment: The company signed a pact with Vivani for a long-lasting semaglutide implant, which adds to its pipeline optionality but is still early-stage and not an immediate earnings driver. Article Title
• Negative Sentiment: Recent prescription-tracker data pointed to a slowdown in demand for the oral Wegovy pill in the U.S., raising concerns that growth in Novo Nordisk’s GLP-1 franchise may be cooling after a strong run. Article Title
• Negative Sentiment: The stock also came under pressure in recent trading after falling more than the broader market, reflecting investor caution around near-term GLP-1 growth trends and valuation. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.